AstraZeneca Gains CDSCO Approval for Trastuzumab Deruxtecan Plus Pertuzumab in HER2-Positive Breast Cancer

AstraZeneca's CDSCO clearance for the Trastuzumab Deruxtecan plus Pertuzumab combination signals a meaningful shift in India's regulatory posture toward antibody-drug conjugate combination regimens, one that local manufacturing partners and biosimilar developers in the HER2 space should read carefully.

The approval covers unresectable or metastatic HER2-positive breast cancer, adding a dual-agent biologic regimen to the Indian market. For contract manufacturers and fill-finish operations already handling ADC or monoclonal antibody programmes, the clearance introduces a more complex sterility assurance and handling profile than single-agent biologics, particularly given the cytotoxic payload carried by Trastuzumab Deruxtecan.

From a regulatory affairs standpoint, CDSCO's willingness to evaluate this combination regimen reflects alignment with global review precedents set by the US FDA and EMA, compressing the gap between international approvals and Indian market entry. For regulatory leads tracking India's New Drugs and Clinical Trials Rules, the approval reinforces that combination biologics with prior global authorisation are moving through the CDSCO pathway with increasing predictability.

Biosimilar developers monitoring the HER2 landscape face a more layered competitive picture. Pertuzumab biosimilars are already in development globally; the combination approval raises the reference product bar and may influence how Indian developers structure their clinical comparability packages under ICH Q5E and applicable CDSCO biosimilar guidelines.

Supply chain and QA leads at Indian biologics sites should note that ADC handling requirements, cold chain integrity, containment controls, and operator safety protocols, will need to be validated against the combination's specific stability and compatibility data before any local packaging or distribution activity can be qualified.

The CDSCO nod positions AstraZeneca to expand HER2-positive breast cancer treatment access in India, with downstream implications for how combination biologic approvals are structured and benchmarked across the subcontinent's regulatory framework going forward.

Source: Media4Growth via Indian Pharma Post, 10 June 2026.